V-ATPase is a candidate therapeutic target for Ewing sarcoma.
about
Yeast phosphofructokinase-1 subunit Pfk2p is necessary for pH homeostasis and glucose-dependent vacuolar ATPase reassemblyTM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cellsMetformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugCancer: fundamentals behind pH targeting and the double-edged approachMicroenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy.Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD.Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancerEvidence-based support for the use of proton pump inhibitors in cancer therapyBafilomycin A1 inhibits the growth and metastatic potential of the BEL-7402 liver cancer and HO-8910 ovarian cancer cell lines and induces alterations in their microRNA expressionThe Function of V-ATPases in CancerThe a3 isoform of subunit a of the vacuolar ATPase localizes to the plasma membrane of invasive breast tumor cells and is overexpressed in human breast cancer.Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.Saccharomyces cerevisiae vacuolar H+-ATPase regulation by disassembly and reassembly: one structure and multiple signals.Recent Insights into the Structure, Regulation, and Function of the V-ATPasesCancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation.Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells.Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells.The Role of Autophagy in the Maintenance of Stemness and Differentiation of Mesenchymal Stem Cells.The acidic microenvironment as a possible niche of dormant tumor cells.Intratumoral acidosis fosters cancer-induced bone pain through the activation of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinomaMetabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy.Regulation of V-ATPase Assembly in Nutrient Sensing and Function of V-ATPases in Breast Cancer MetastasisVacuolar H+-ATPase: An Essential Multitasking Enzyme in Physiology and Pathophysiology
P2860
Q27931757-8B24DFBF-9AF9-4C60-BDD7-AB83BD8FAE10Q28119089-42000B44-A949-4D73-9E75-C489CEAD1696Q28538155-CBFF9A04-97BF-42BB-A5B7-5E263EF578D1Q28821351-09BC1266-B57F-458F-A5D2-60100BDCD9E8Q34573748-DF5F54A9-1F3B-490F-B32D-FA6380ED9E76Q35348175-9BF167A4-F128-4594-900E-8DD6194A84E1Q35605579-D2834C0B-6BD3-4397-8F4D-EEA31D43255EQ35987082-42B759F6-8237-4C4A-AD3C-09A14711DF47Q36310900-2C1E508A-2FA8-4E83-A65B-1279D60B5095Q36336343-E5B05367-16B7-4169-BBAC-85D003889016Q37169505-7A5104C7-B6DC-4DCA-8CDA-F5270264F6CBQ37564675-F58C3682-88D3-442C-A6B0-4147DFC135C7Q37665338-7E8FF8DD-2648-47F3-8EE4-2D6882865B7BQ37706150-C059BDCF-31DD-4EEE-83CC-9703AB360FA4Q38202559-A1C59F49-E8DC-4415-AE7C-FB4B379246E6Q38593788-07A1BD7E-95D2-4866-A557-676E15D23A97Q38728887-2B37235C-D740-477A-8CDF-FE7C940118C4Q38773386-6CC2C31A-458B-4C2C-B43D-93BA9E7E0BF5Q38825585-5FAB8540-6D0D-4E3E-B4DF-40625A0A2C19Q38866428-157FE3D1-8918-4153-8A19-B76FF8490CC9Q38970616-74DEC78A-BA72-411F-B215-067061521973Q39195025-C5A424C8-D3D2-431B-979D-F0CA801FEEB9Q41551822-5E1A8B8A-6BE0-4E7F-921F-EC1FB46F3185Q52757920-2EFF8FF7-C5BD-43FA-B543-9B83E4EF3370Q57109591-59FD4B6D-FE05-45A6-8DAA-04C46AF0001AQ59072675-C17993B1-0BFB-41F7-83D0-7F753852B97E
P2860
V-ATPase is a candidate therapeutic target for Ewing sarcoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
V-ATPase is a candidate therapeutic target for Ewing sarcoma.
@en
V-ATPase is a candidate therapeutic target for Ewing sarcoma.
@nl
type
label
V-ATPase is a candidate therapeutic target for Ewing sarcoma.
@en
V-ATPase is a candidate therapeutic target for Ewing sarcoma.
@nl
prefLabel
V-ATPase is a candidate therapeutic target for Ewing sarcoma.
@en
V-ATPase is a candidate therapeutic target for Ewing sarcoma.
@nl
P50
P1476
V-ATPase is a candidate therapeutic target for Ewing sarcoma.
@en
P2093
Manuela Salerno
P304
P356
10.1016/J.BBADIS.2013.04.003
P407
P50
P577
2013-04-08T00:00:00Z